Search Results - "Guedan, Sonia"

Emerging Cellular Therapies for Cancer by Guedan, Sonia, Ruella, Marco, June, Carl H

“…Genetically engineered T cells are powerful new medicines, offering hope for curative responses in patients with cancer. Chimeric antigen receptor (CAR) T…”
Get full text

CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge by Guedan, Sonia, Alemany, Ramon

“…Adoptive transfer of chimeric antigen receptor (CAR)-modified T cells has resulted in unprecedented rates of long-lasting complete responses in patients with…”
Get full text

CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape by Rodriguez-Garcia, Alba, Palazon, Asis, Noguera-Ortega, Estela, Powell, Jr, Daniel J, Guedan, Sonia

“…Chimeric antigen receptor (CAR) T cell therapies have demonstrated remarkable efficacy for the treatment of hematological malignancies. However, in patients…”
Get full text

Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor Efficacy by Fajardo, Carlos Alberto, Guedan, Sonia, Rojas, Luis Alfonso, Moreno, Rafael, Arias-Badia, Marcel, de Sostoa, Jana, June, Carl H, Alemany, Ramon

“…Antiviral immune responses present a major hurdle to the efficacious use of oncolytic adenoviruses as cancer treatments. Despite the existence of a highly…”
Get full text

ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells by Guedan, Sonia, Chen, Xi, Madar, Aviv, Carpenito, Carmine, McGettigan, Shannon E., Frigault, Matthew J., Lee, Jihyun, Posey, Avery D., Scholler, John, Scholler, Nathalie, Bonneau, Richard, June, Carl H.

“…With the notable exception of B-cell malignancies, the efficacy of chimeric antigen receptor (CAR) T cells has been limited, and CAR T cells have not been…”
Get full text

The role of chimeric antigen receptor T cells targeting more than one antigen in the treatment of B-cell malignancies by Brillembourg, Helena, Martínez-Cibrián, Núria, Bachiller, Mireia, Alserawan, Leticia, Ortiz-Maldonado, Valentín, Guedan, Sònia, Delgado, Julio

“…Several products containing chimeric antigen receptor T cells targeting CD19 (CART19) have been approved for the treatment of patients with relapsed/refractory…”
Get full text

Hyaluronidase Expression by an Oncolytic Adenovirus Enhances Its Intratumoral Spread and Suppresses Tumor Growth by Guedan, Sonia, Rojas, Juan José, Gros, Alena, Mercade, Elena, Cascallo, Manel, Alemany, Ramon

“…Successful virotherapy requires efficient virus spread within tumors. We tested whether the expression of hyaluronidase, an enzyme which dissociates the…”
Get full text

CAR affinity modulates the sensitivity of CAR-T cells to PD-1/PD-L1-mediated inhibition by Andreu-Saumell, Irene, Rodriguez-Garcia, Alba, Mühlgrabner, Vanessa, Gimenez-Alejandre, Marta, Marzal, Berta, Castellsagué, Joan, Brasó-Maristany, Fara, Calderon, Hugo, Angelats, Laura, Colell, Salut, Nuding, Mara, Soria-Castellano, Marta, Barbao, Paula, Prat, Aleix, Urbano-Ispizua, Alvaro, Huppa, Johannes B., Guedan, Sonia

“…Chimeric antigen receptor (CAR)-T cell therapy for solid tumors faces significant hurdles, including T-cell inhibition mediated by the PD-1/PD-L1 axis. The…”
Get full text

Engineering and Design of Chimeric Antigen Receptors by Guedan, Sonia, Calderon, Hugo, Posey, Jr, Avery D, Maus, Marcela V

“…T cells engineered with chimeric antigen receptors (CARs) have emerged as a potent new class of therapeutics for cancer, based on their remarkable potency in…”
Get full text

Minimal RB-responsive E1A Promoter Modification to Attain Potency, Selectivity, and Transgene-arming Capacity in Oncolytic Adenoviruses by Rojas, Juan J, Guedan, Sonia, Searle, Peter F, Martinez-Quintanilla, Jordi, Gil-Hoyos, Raúl, Alcayaga-Miranda, Francisca, Cascallo, Manel, Alemany, Ramon

“…Oncolytic adenoviruses are promising anticancer agents due to their ability to self-amplify at the tumor mass. However, tumor stroma imposes barriers difficult…”
Get full text

Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies by Glez-Vaz, Javier, Azpilikueta, Arantza, Olivera, Irene, Cirella, Assunta, Teijeira, Alvaro, Ochoa, Maria C, Alvarez, Maite, Eguren-Santamaria, Iñaki, Luri-Rey, Carlos, Rodriguez-Ruiz, Maria E, Nie, Xinxin, Chen, Lieping, Guedan, Sonia, Sanamed, Miguel F, Perez Gracia, Jose Luis, Melero, Ignacio

“…On the basis of efficacy in mouse tumor models, multiple CD137 (4-1BB) agonist agents are being preclinically and clinically developed. The costimulatory…”
Get full text

Immobilizing A Moving Target: CAR T Cells Hit CD22 by Guedan, Sonia, Delgado, Julio

“…A key mechanism of resistance to chimeric antigen receptor-modified T cells (CAR-T) is loss or downregulation of target antigens. Low antigen expression on…”
Get full text

Analysis of CAR-Mediated Tonic Signaling by Calderon, Hugo, Mamonkin, Maksim, Guedan, Sonia

“…CARs are synthetic receptors designed to drive antigen-specific activation upon binding of the scFv to its cognate antigen. However, CARs can also elicit…”
Get more information

Choosing the Right Tool for Genetic Engineering: Clinical Lessons from Chimeric Antigen Receptor-T Cells by Irving, Melita, Lanitis, Evripidis, Migliorini, Denis, Ivics, Zoltán, Guedan, Sonia

“…T cell modification with genes that encode chimeric antigen receptors (CAR-T cells) has shown tremendous promise for the treatment of B cell malignancies. The…”
Get more information

Analysis of Antitumor Effects of CAR-T Cells in Mice with Solid Tumors by Rodriguez-Garcia, Alba, Watanabe, Keisuke, Guedan, Sonia

“…Animal models provide an essential tool to study the efficacy of CAR-T cell treatments. Most of the current works test human CAR-T cells in immunodeficient…”
Get more information

Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells by Kawalekar, Omkar U., O’Connor, Roddy S., Fraietta, Joseph A., Guo, Lili, McGettigan, Shannon E., Posey, Avery D., Patel, Prachi R., Guedan, Sonia, Scholler, John, Keith, Brian, Snyder, Nathaniel W., Blair, Ian A., Milone, Michael C., June, Carl H.

“…Chimeric antigen receptors (CARs) redirect T cell cytotoxicity against cancer cells, providing a promising approach to cancer immunotherapy. Despite extensive…”
Get full text

Single residue in CD28-costimulated CAR-T cells limits long-term persistence and antitumor durability by Guedan, Sonia, Madar, Aviv, Casado-Medrano, Victoria, Shaw, Carolyn, Wing, Anna, Liu, Fang, Young, Regina M, June, Carl H, Posey, Jr, Avery D

“…Chimeric antigen receptor-T (CAR-T) cell therapies can eliminate relapsed and refractory tumors, but the durability of antitumor activity requires in vivo…”
Get full text

An NK-like CAR T cell transition in CAR T cell dysfunction by Good, Charly R., Aznar, M. Angela, Kuramitsu, Shunichiro, Samareh, Parisa, Agarwal, Sangya, Donahue, Greg, Ishiyama, Kenichi, Wellhausen, Nils, Rennels, Austin K., Ma, Yujie, Tian, Lifeng, Guedan, Sonia, Alexander, Katherine A., Zhang, Zhen, Rommel, Philipp C., Singh, Nathan, Glastad, Karl M., Richardson, Max W., Watanabe, Keisuke, Tanyi, Janos L., O’Hara, Mark H., Ruella, Marco, Lacey, Simon F., Moon, Edmund K., Schuster, Stephen J., Albelda, Steven M., Lanier, Lewis L., Young, Regina M., Berger, Shelley L., June, Carl H.

“…Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable success in hematological malignancies but remains ineffective in solid tumors, due in…”
Get full text

Genome Editing in Engineered T Cells for Cancer Immunotherapy by Bonini, Chiara, Chapuis, Aude G, Hudecek, Michael, Guedan, Sonia, Magnani, Chiara, Qasim, Waseem

“…Advanced gene transfer technologies and profound immunological insights have enabled substantial increases in the efficacy of anticancer adoptive cellular…”
Get more information

Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager by Wing, Anna, Fajardo, Carlos Alberto, Posey, Jr, Avery D, Shaw, Carolyn, Da, Tong, Young, Regina M, Alemany, Ramon, June, Carl H, Guedan, Sonia

“…T cells expressing chimeric antigen receptors (CART) have shown significant promise in clinical trials to treat hematologic malignancies, but their efficacy in…”
Get more information